SOTYKTU 6 mg/1

Deucravacitinib, the active ingredient in SOTYKTU, is a Tyrosine kinase 2 (TYK2) inhibitor presented as a 6 mg/1 tablet, film coated for oral use. It is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

GNH USA supplies SOTYKTU as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

SOTYKTU is indicated for the treatment of immune-mediated diseases, specifically moderate to severe plaque psoriasis. It is designed to help manage symptoms in adults who require systemic therapy or phototherapy.

- Plaque psoriasis: Reduces the severity and extent of skin lesions and improves overall skin condition.

SOTYKTU may cause various side effects, ranging from common to serious. Patients should be monitored closely for any adverse reactions.

Common Side Effects: - Upper respiratory tract infections, such as nasopharyngitis. - Headache. - Diarrhea. - Nausea. - Fatigue. - Acne. - Back pain. - Influenza.

Serious or Rare Side Effects: - Serious infections, including opportunistic infections. - Malignancies, including skin cancers. - Major cardiovascular events. - Liver problems, including elevated liver enzymes. - Hypersensitivity reactions.

SOTYKTU should be used with caution in certain patient populations and conditions. Patients and healthcare providers should be aware of the following precautions.

- Infections: Monitor for signs of infection before and during treatment. - Malignancies: Regular skin examinations are recommended to monitor for skin cancers. - Cardiovascular events: Assess cardiovascular risk factors before initiating treatment. - Liver function: Monitor liver enzymes regularly during treatment. - Hypersensitivity: Discontinue use if signs of hypersensitivity reactions occur. - Pregnancy and breastfeeding: Safety in pregnancy and breastfeeding has not been established; consult healthcare provider. - Store below 25°C: Keep in the original pack, protect from moisture.

SOTYKTU may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Healthcare providers should be aware of the following interactions.

Major Interactions (Avoid): - Immunosuppressants: Increased risk of infections and malignancies. - Live vaccines: Avoid concurrent use due to potential for vaccine-related infections. - Strong CYP3A4 inducers: May decrease the effectiveness of SOTYKTU.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: May require dose adjustment. - Moderate CYP3A4 inhibitors: May increase the risk of side effects. - Anticoagulants: Increased risk of bleeding. - Immunomodulators: May enhance immunosuppressive effects.